Deals were signed with Oncolys, Advantagene, and H. Lee Moffitt Cancer Center.
Introgen Technical Services (ITS) inked agreements to manufacture biological materials for Advantagene and the H. Lee Moffitt Cancer Center. Additionally, the company expanded its collaboration with Oncolys BioPharma. Aggregate proceeds to ITS from these contracts total more than $1 million.
ITS will complete additional GMP production services related to Oncolys’ cancer drug candidate. Telomelysin® is an adenovirus type 5 vector carrying the human telomerase reverse transcriptase (hTERT) gene. It is being studied in Phase I trials for the treatment of head and neck cancers, hepatocellular carcinoma, and esophageal cancer.
ITS will also manufacture Advantagene’s ProstAtak™, an adenovirus type 5 vector carrying the herpes simplex thymidine kinase gene. This product is being evaluated in Phase II as a treatment for prostate cancer.
Additionally, the company will produce H. Lee Moffitt’s adenovirus type 5 vector carrying a gene for Survivin protein production. This compound has potential applications in the treatment of small-cell lung cancer.
To comment on this story, go to BLOGbiotech.